Page last updated: 2024-11-04

vesnarinone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID5663
CHEMBL ID17423
CHEBI ID31237
SCHEMBL ID50993
MeSH IDM0123478

Synonyms (67)

Synonym
6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-3,4-dihydro-2(1h)-quinolinone
arkin
6-[4-(3,4-dimethoxybenzoyl)piperazin-1-yl]-3,4-dihydro-1h-quinolin-2-one
arkin-z
vesnarinone
3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2-(1h)-quinolinone
opc-8212
81840-15-5
piperazine, 1-(3,4-dimethoxybenzoyl)-4-(1,2,3,4-tetrahydro-2-oxo-6-quinolinyl)-
vesnarinona [spanish]
1-(1,2,3,4-tetrahydro-2-oxo-6-quinolyl)-4-veratroylpiperazine
drg-0210
vesnarinone [usan:inn:jan]
6-(4-(3,4-dimethoxybenzoyl)-1-piperazinyl)-3,4-dihydro-2(1h)-quinolone
vesnarinonum [latin]
3,4-dihydro-6-(4-(3,4-dimethoxybenzoyl)-1-piperazinyl)-2(1h)-quinolinone
6-(4-(3,4-dimethoxybenzoyl)-1-piperazinyl)-3,4-dihydro-2(1h)-
ccris 1451
brn 5644229
piteranometozine
1-(3,4-dimethoxybenzoyl)-4-(1,2,3,4-tetrahydro-2-oxo-6-quinolinyl)piperazine
vesnarinone (jan/usan/inn)
D01690
arkin z (tn)
CHEMBL17423 ,
arkin z
6-[4-(3,4-dimethoxy-benzoyl)-piperazin-1-yl]-3,4-dihydro-1h-quinolin-2-one(opc-8212)
6-[4-(3,4-dimethoxy-benzoyl)-piperazin-1-yl]-3,4-dihydro-1h-quinolin-2-one
[4-(3,4-dihydro-quinolin-6-yl)-piperazin-1-yl]-(3,4-dimethoxy-phenyl)-methanone
6-(4-(3,4-dimethoxybenzoyl)piperazin-1-yl)-3,4-dihydroquinolin-2(1h)-one
bdbm50016980
vesnarinona
unii-5cow40ev8m
vesnarinonum
5cow40ev8m ,
FT-0630896
vesnarinone [who-dd]
vesnarinone [vandf]
vesnarinone [inn]
vesnarinone [jan]
vesnarinone [mart.]
vesnarinone [mi]
vesnarinone [usan]
SCHEMBL50993
CS-5387
HY-15297
DTXSID80231411
6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-3,4-dihydrocarbostyril
ZVNYJIZDIRKMBF-UHFFFAOYSA-N
6-{4-[(3,4-dimethoxyphenyl)carbonyl]piperazin-1-yl}-1,2,3,4-tetrahydroquinolin-2-one
J-690354
5-{3-[3-(2-chloro-4-fluorophenoxy)-1-azetidinyl]-5-(methoxymethyl)-4h-1,2,4-triazol-4-yl}-2-methoxypyridine
EX-A718
CHEBI:31237
arkin (tn)
AKOS027475338
mfcd00867124
vesnarinone(opc8212)
DB12082
opc 8212;opc-8212;opc8212
BCP15943
Q7923264
benzyl2-acetamido-4,6-o-benzylidene-2-deoxy-alpha-d-glucopyranoside
NCGC00510509-02
opc-8212; piteranometozine; arkin
MS-26657
A857063

Research Excerpts

Overview

Vesnarinone is an important new drug that significantly decreases mortality rates in severe congestive heart failure. Its use is associated with a relatively high incidence (approximately 1%) of agranulocytosis. Vesnarin one is a new, non vasodilating cardiotonic agent.

ExcerptReferenceRelevance
"Vesnarinone is a synthetic quinolinone derivative used in the treatment of cardiac failure and cancer. "( Vesnarinone suppresses TNFα mRNA expression by inhibiting valosin-containing protein.
Aizawa, S; Ando, H; Azuma, M; Handa, H; Hiramoto, M; Hotta, K; Iizumi, Y; Imai, T; Ito, T; Kabe, Y; Nabeshima, R; Nashimoto, A; Okada, A; Sakamoto, S; Sakata-Sogawa, K; Shima, D; Suzuki, M; Tokunaga, M; Watanabe, H; Yamaguchi, Y; Yasumura, E, 2013
)
3.28
"Vesnarinone is a synthesized positive oral inotropic agent that has multiple biological activities on mammalian cells both in vitro and in vivo. "( Vesnarinone inhibits angiogenesis and tumorigenicity of human oral squamous cell carcinoma cells by suppressing the expression of vascular endothelial growth factor and interleukin-8.
Harada, K; Sato, M; Yoshida, H, 2005
)
3.21
"Vesnarinone is a novel synthetic oral inotropic agent that has been successfully used for treatment of patients with congestive heart failure. "( Vesnarinone inhibits nucleoside and nucleobase transport.
Gelfand, EW; Kumakura, T; Takase, K; Terada, N, 1995
)
3.18
"Vesnarinone is an important new drug that significantly decreases mortality rates in severe congestive heart failure; however, its use is associated with a relatively high incidence (approximately 1%) of agranulocytosis. "( Metabolism of vesnarinone by activated neutrophils: implications for vesnarinone-induced agranulocytosis.
Uetrecht, JP; Whitfield, D; Zahid, N, 1994
)
2.09
"Vesnarinone is a new, non vasodilating cardiotonic agent. "( Effects of vesnarinone (OPC-8212) on Ca(2+)-activated K channels and cytosolic Ca2+ in cultured smooth muscle cells from porcine coronary artery.
Miyoshi, Y; Nakaya, Y; Nomura, M; Saito, K; Shono, M; Wakatsuki, T, 1994
)
2.12
"Vesnarinone (OPC-8212) is a new positive inotropic agent that augments myocardial contractility. "( Vesnarinone-induced granulocytopenia: incidence in Japan and recommendations for safety.
Asanoi, H; Furusawa, S; Ohashi, Y, 1996
)
3.18
"Vesnarinone is a novel oral agent that improves survival and symptoms of patients with dilated cardiomyopathy. "( Dose dependence of chronic positive inotropic effect of vesnarinone in patients with congestive heart failure due to idiopathic or ischemic cardiomyopathy.
Becker, LC; Feldman, AM; Kasper, EK; Kass, DA; Van Anden, E; White, WB, 1996
)
1.98
"Vesnarinone is an experimental drug that has been used successfully in the treatment of congestive heart failure patients. "( Vesnarinone is a selective inhibitor of macrophage TNF(alpha) release.
Fong, M; Jacob, CO; Kambayashi, T; Mazurek, N; Strassmann, G; Wei, N,
)
3.02
"Vesnarinone is a non-glycoside positive inotropic drug that has immunomodulating actions. "( Prolongation of murine cardiac allograft survival with vesnarinone.
Furukawa, Y; Hirozane, T; Matoba, Y; Matsui, S; Matsumori, A; Sasayama, S, 1997
)
1.99
"Vesnarinone is an experimental drug which is known to inhibit TNF alpha release."( Vesnarinone inhibits immune-mediated but not Fas (CD95) agonist-mediated hepatic injury.
Baumann, H; Jacob, CO; Kambayashi, T; Lazarus, DD; Strassmann, G; Yato-Kioka, M, 1997
)
2.46
"Vesnarinone is a positive inotropic agent used for treating congestive heart failure. "( Vesnarinone exhibits antitumor effect against myeloid leukemia cells via apoptosis.
Arima, N; Arimura, K; Fujiwara, H; Hidaka, S; Kukita, T; Matsushita, K; Otsubo, H; Tanaka, H; Yamaguchi, K, 1997
)
3.18
"Vesnarinone is a new and novel inotropic drug that has unique and complex mechanisms of action. "( Vesnarinone: a new inotropic agent for treating congestive heart failure.
Cavusoglu, E; Frishman, WH; Klapholz, M, 1995
)
3.18
"Vesnarinone is a novel synthetic inotropic agent. "( Vesnarinone inhibits adenosine uptake in endothelial cells, smooth muscle cells and myocytes, and mediates cytoprotection.
Fong, M; Hori, M; Kambayashi, T; Kitakaze, M; Minamino, T; Node, K; Okuyama, Y; Terada, N; Yoshitake, M, 1997
)
3.18
"Vesnarinone (OPC-8212) is a synthetic quinolinone derivative with inotropic and immunomodulatory effects. "( The effect of vesnarinone on TNF alpha production in human peripheral blood mononuclear cells and microglia: a preclinical study for the treatment of multiple sclerosis.
Bergey, G; Bielekova, B; Clarence-Smith, K; Dhib-Jalbut, S; Jiang, H; Johnson, KP; Martin, R; Okazaki, H, 1999
)
2.11
"Vesnarinone is an orally administered inotropic agent that is metabolized in vitro by the cytochrome P450 (CYP) isozymes CYP3A4 and CYP2E1. "( Effect of disulfiram-mediated CYP2E1 inhibition on the disposition of vesnarinone.
Bramer, SL; Cowart, TD; Frye, RF; Tammara, B, 1999
)
1.98
"Vesnarinone is a selective blocker of IK with a unique drug-channel interaction."( Carvedilol and vesnarinone: new antiarrhythmic approach in heart failure therapy.
Cheng, JH; Kamiya, K; Kodama, I, 2001
)
1.38
"Vesnarinone is an effective inotropic agent for treating congestive heart failure, but its clinical usage is restricted because of the severe side effect of agranulocytosis. "( Vesnarinone causes oxidative damage by inhibiting catalase function through ceramide action in myeloid cell apoptosis.
Daido, N; Domae, N; Iwai, K; Kitano, T; Kondo, T; Okazaki, T; Suzuki, Y; Tashima, M; Uchiyama, T; Umehara, H; Watanabe, M, 2002
)
3.2

Effects

Vesnarinone has been shown to be a unique anti-proliferating, differentiation-inducing and apoptosis inducing drug against several human malignancies. It has no direct inhibitory activity against the reverse transcriptase of HIV-1, syncytium formation in short term assays, or retroviral protease.

ExcerptReferenceRelevance
"Vesnarinone has been shown to be a unique anti-proliferating, differentiation-inducing and apoptosis inducing drug against several human malignancies, including leukemia and several solid tumors. "( Vesnarinone: a differentiation-inducing anti-cancer drug.
Fujimori, T; Hino, S; Kawamata, H; Nakashiro, K; Omotehara, F; Uchida, D, 2003
)
3.2
"Vesnarinone has no direct inhibitory activity against the reverse transcriptase of HIV-1, syncytium formation in short term assays, or retroviral protease."( Vesnarinone inhibits production of HIV-1 in cultured cells.
Chen, IS; Ikeda, M; Kitajima, I; Maruyama, I; Maruyama, Y; Nakai, S; Nakajima, T; Osame, M; Yabu-uchi, Y; Zhao, JQ, 1993
)
2.45
"Vesnarinone (VES) has been used for treatment of patients with congestive heart failure. "( Effects of vesnarinone, a novel orally active inotropic agent with an immunosuppressive action, on experimental cardiac transplantation in rats.
DiSesa, VJ; Fyfe, BS; Goldstein, C; Mohiuddin, M; Momeni, R; Shen, Z; Whitman, GJ; Yokoyama, H, 1996
)
2.13
"Vesnarinone has yielded controversial results on morbidity in patients with congestive heart failure. "( Effect of vesnarinone on cardiac function in patients with severe congestive heart failure.
Cocca-Spofford, D; Dec, GW; DiSalvo, TG; Picard, MH; Scherrer-Crosbie, M; Semigran, MJ, 1998
)
2.15
"Vesnarinone has also been reported to inhibit both nucleoside and nucleobase transport."( Antitumor effect of vesnarinone on human hepatocellular carcinoma cell lines.
Kato, A; Kubo, K; Matsuzaki, Y; Okita, K; Terai, S, 1999
)
1.35
"Vesnarinone has been shown to inhibit tumor necrosis factor-alpha (TNF alpha) produced by mitogen stimulated macrophages, and to inhibit phosphodiesterase (PDE) type III in cardiac muscle."( The effect of vesnarinone on TNF alpha production in human peripheral blood mononuclear cells and microglia: a preclinical study for the treatment of multiple sclerosis.
Bergey, G; Bielekova, B; Clarence-Smith, K; Dhib-Jalbut, S; Jiang, H; Johnson, KP; Martin, R; Okazaki, H, 1999
)
1.39

Treatment

Vesnarinone treatment combined with radiation resulted in a higher antitumour activity compared with a single treatment. The treatment of vesNarinone did not modify the phenotype of myofibroblast cells in culture.

ExcerptReferenceRelevance
"The vesnarinone treatment resulted in a significant suppression of tumor growth."( Characteristics of antitumor activity of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]- 2(1H)-quinolinone (vesnarinone) against a human adenoid squamous carcinoma-forming cell line grown in athymic nude mice.
Adachi, M; Bando, T; Harada, K; Kawai, K; Nakai, S; Nakashiro, K; Sato, M; Shirakami, T; Yoshida, H, 1995
)
0.98
"Vesnarinone treatment combined with radiation resulted in a higher antitumour activity compared with a single treatment with either vesnarinone or radiation alone."( Enhancement of anticancer effects of radiation and conventional anticancer agents by a quinolinone derivative, vesnarinone: studies on human gastric cancer tissue xenografts in nude mice.
Adachi, M; Hozumi, M; Izumi, K; Kawai, K; Konishi, Y; Sato, M,
)
1.06
"The treatment of vesnarinone did not modify the phenotype of myofibroblast cells in culture."( Inhibition of hyaluronan synthesis by vesnarinone in cultured human myofibroblasts.
Adachi, M; Amuro, Y; Hada, T; Higashino, K; Ohkawa, T; Taguchi, T; Takahashi, M; Ueki, N, 2000
)
0.91

Toxicity

ExcerptReferenceRelevance
"This article reviews the precautions and adverse effects associated with vesnarinone use, and the potential mechanisms responsible for these complications as well as suggested treatment strategies."( Precautions for use and adverse effects of vesnarinone: potential mechanisms and future therapies.
Bertolet, BD, 2004
)
0.82

Pharmacokinetics

There is no evidence of pharmacokinetic interaction between vesnarinone and gemcitabine. There was a significant decrease in maximum concentration (Cmax) and increase in time to Cmax (tmax) during treatment with famotidine.

ExcerptReferenceRelevance
"5-, 15-, 30-, 60-, 120-, or 240-mg dose in a sequentially ascending order to 21 male healthy volunteers to determine the pharmacokinetic profile."( Pharmacokinetic profile of OPC-8212 in humans: a new, nonglycosidic, inotropic agent.
Ishizaki, T; Ohnishi, A, 1988
)
0.27
" After oral doses of 10 mg/kg of 14C- OPC -8212 to rats and beagle dogs, the Tmax, Cmax and T1/2 values of OPC -8212 were 4 h, 2995 ng eq/ml, and 3-4 h in rats and 1 h, 2244 ng eq/ml and 5-6 h in beagle dogs, respectively."( Pharmacokinetics of a new positive inotropic agent, 3, 4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-qu inolinone (OPC-8212), in the rat, rabbit, beagle dog and rhesus monkey.
Miyamoto, G; Sasabe, H, 1984
)
0.27
" A significant decrease in maximum concentration (Cmax) and increase in time to Cmax (tmax) was observed for vesnarinone during treatment with famotidine, whereas area under the concentration-time curve (AUC) was similar for both treatments."( Effect of increasing gastric pH with famotidine on the absorption and oral pharmacokinetics of the inotropic agent vesnarinone.
Bramer, SL; Cowart, DT; Kisicki, J; Koneru, B; Noorisa, M, 1998
)
0.72
"To evaluate the maximum-tolerated dose, dose-limiting toxicities (DLTs), and pharmacokinetic profile of vesnarinone given once daily in combination with gemcitabine."( Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancer.
Drengler, RL; Eckhardt, SG; Felton, SA; Garner, AM; Hammond, LA; Hidalgo, M; Mallikaarjun, S; Patnaik, A; Rowinsky, EK; Siu, LL; Tammara, BK; Von Hoff, DD, 2000
)
0.76
" Pharmacokinetic studies of vesnarinone revealed significant interpatient variability at any given dose level."( Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancer.
Drengler, RL; Eckhardt, SG; Felton, SA; Garner, AM; Hammond, LA; Hidalgo, M; Mallikaarjun, S; Patnaik, A; Rowinsky, EK; Siu, LL; Tammara, BK; Von Hoff, DD, 2000
)
0.84
" There is no evidence of pharmacokinetic interaction between vesnarinone and gemcitabine."( Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancer.
Drengler, RL; Eckhardt, SG; Felton, SA; Garner, AM; Hammond, LA; Hidalgo, M; Mallikaarjun, S; Patnaik, A; Rowinsky, EK; Siu, LL; Tammara, BK; Von Hoff, DD, 2000
)
0.79

Compound-Compound Interactions

The recommended dose of vesnarinone for phase II evaluations is 90 mg orally once daily with gemcitabine 1,000 mg/m(2) IV on days 1, 8, and 15 every 4 weeks.

ExcerptReferenceRelevance
" To evaluate the anti-cancer activity of vesnarinone in combination with irradiation, we investigated the cytostatic and cytotoxic effects on human lung cancer cell lines (PC-9 and Lu 134A) using MTT assay and isobologram analysis."( Effects of quinolinone derivative, vesnarinone, in combination with irradiation on human lung cancer cell lines.
Fujita, M; Fujita, T; Higashino, K; Tsuchida, T,
)
0.67
" We have studied the anti-cancer effect of vesnarinone in combination with cisplatin, VP-16 (etoposide) and gemcitabine, against human lung cancer cell lines (PC-9 and Lu 134A) using the MTT assay and isobologram analysis."( Effect of vesnarinone in combination with anti-cancer drugs on lung cancer cell lines.
Fujita, M; Higashino, K; Tsuchida, T, 1999
)
0.97
"To evaluate the maximum-tolerated dose, dose-limiting toxicities (DLTs), and pharmacokinetic profile of vesnarinone given once daily in combination with gemcitabine."( Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancer.
Drengler, RL; Eckhardt, SG; Felton, SA; Garner, AM; Hammond, LA; Hidalgo, M; Mallikaarjun, S; Patnaik, A; Rowinsky, EK; Siu, LL; Tammara, BK; Von Hoff, DD, 2000
)
0.76
"Twenty-six patients were treated with oral vesnarinone once daily on a continuous schedule at doses of 60, 90, 120, 150, and 180 mg in combination with intravenous (IV) gemcitabine at a dose of 1,000 mg/m(2) on days 1, 8, and 15 every 4 weeks."( Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancer.
Drengler, RL; Eckhardt, SG; Felton, SA; Garner, AM; Hammond, LA; Hidalgo, M; Mallikaarjun, S; Patnaik, A; Rowinsky, EK; Siu, LL; Tammara, BK; Von Hoff, DD, 2000
)
0.81
"When combined with gemcitabine, the recommended dose of vesnarinone for phase II evaluations is 90 mg orally once daily with gemcitabine 1,000 mg/m(2) IV on days 1, 8, and 15 every 4 weeks."( Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancer.
Drengler, RL; Eckhardt, SG; Felton, SA; Garner, AM; Hammond, LA; Hidalgo, M; Mallikaarjun, S; Patnaik, A; Rowinsky, EK; Siu, LL; Tammara, BK; Von Hoff, DD, 2000
)
0.79

Dosage Studied

Dose-dependent increase in mortality was identified for vesnarinone 30-120 mg/day. A dose-response curve was constructed with vesNarinone concentrations ranging from 10(-4 ) to 10(-9 ) mol/L.

ExcerptRelevanceReference
" The mean fraction of the daily dose excreted unchanged in urine over the dosing interval (fe0-r) during days 9 to 15 ranged from 19."( Pharmacokinetic profile of OPC-8212 in humans: a new, nonglycosidic, inotropic agent.
Ishizaki, T; Ohnishi, A, 1988
)
0.27
" Further research into the appropriate mechanisms of action and proper dosing of these drugs may lead to a renewed interest in the use of positive inotropes for chronic heart failure."( Reassessment of digoxin and other low-dose positive inotropes in the treatment of chronic heart failure.
Gheorghiade, M; Han, D; Tauke, J, 1994
)
0.29
" A dose-response curve was constructed with vesnarinone concentrations ranging from 10(-4 ) to 10(-9 ) mol/L."( Differential response to vesnarinone by cardiac fibroblasts isolated from normal and aortic regurgitant hearts.
Borer, JS; Goldfine, SM; Herrold, EM; Ross, JS, 1998
)
0.86
" of the high dosage used in the Vesnarinone Study Group Trial (VSGT), and of both dosages used in the Vesnarinone Trial (VEST)] a dose-dependent increase in mortality was identified for vesnarinone 30-120 mg/day."( Clinical characteristics of vesnarinone.
Feldman, AM, 2004
)
0.9
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
organic molecular entityAny molecular entity that contains carbon.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)5.32240.00091.901410.0000AID161281; AID240820; AID408340; AID576612
cGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)IC50 (µMol)11.31330.00002.072410.0000AID1245201; AID219850; AID460693
cGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)IC50 (µMol)9.37000.00031.990110.0000AID1245200; AID219850; AID460692
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (46)

Processvia Protein(s)Taxonomy
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
angiogenesiscGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
negative regulation of cell adhesioncGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
G protein-coupled receptor signaling pathwaycGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
negative regulation of angiogenesiscGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
cellular response to insulin stimuluscGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
negative regulation of cell adhesion mediated by integrincGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
negative regulation of lipid catabolic processcGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwaycGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
cAMP-mediated signalingcGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
oocyte maturationcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
lipid metabolic processcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
G protein-coupled receptor signaling pathwaycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
response to xenobiotic stimuluscGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
cAMP-mediated signalingcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
cGMP-mediated signalingcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
regulation of meiotic nuclear divisioncGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
negative regulation of apoptotic processcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
negative regulation of vascular permeabilitycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
positive regulation of vascular permeabilitycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
steroid hormone mediated signaling pathwaycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
negative regulation of cAMP-mediated signalingcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
positive regulation of oocyte developmentcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
regulation of ribonuclease activitycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
cellular response to cGMPcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
cellular response to transforming growth factor beta stimuluscGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
apoptotic signaling pathwaycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwaycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (20)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
3',5'-cyclic-nucleotide phosphodiesterase activitycGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
cGMP-inhibited cyclic-nucleotide phosphodiesterase activitycGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
protein bindingcGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
protein kinase B bindingcGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
metal ion bindingcGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
3',5'-cyclic-nucleotide phosphodiesterase activitycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
cGMP-inhibited cyclic-nucleotide phosphodiesterase activitycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
protein bindingcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
nuclear estrogen receptor activitycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
metal ion bindingcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
estrogen bindingcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (10)

Processvia Protein(s)Taxonomy
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
endoplasmic reticulumcGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
Golgi apparatuscGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
cytosolcGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
membranecGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
guanyl-nucleotide exchange factor complexcGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
cytosolcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
membranecGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
cytosolcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (50)

Assay IDTitleYearJournalArticle
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID576612Inhibition of human ERG2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
AID1245204Cardiotonic activity in reserpine-pretreated and spontaneously beating rat atria assessed as inotropic activity by measuring contractile force at 100 uM (Rvb = 100%)2015Bioorganic & medicinal chemistry, Sep-15, Volume: 23, Issue:18
Design and discovery of 2-(4-(1H-tetrazol-5-yl)-1H-pyrazol-1-yl)-4-(4-phenyl)thiazole derivatives as cardiotonic agents via inhibition of PDE3.
AID7191020% increase in contractile force (CF) of ferret papillary muscle1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Cardiotonic agents. 5. Fragments from the heterocycle-phenyl-imidazole pharmacophore.
AID460708Positive inotropic activity in isolated reserpine-treated Wistar rat whole atrium assessed as heart rate at 10 uM (Rvb=100+/-3%)2010Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2
Design, synthesis and biological evaluation of 6-(benzyloxy)-4-methylquinolin-2(1H)-one derivatives as PDE3 inhibitors.
AID1245205Toxic cardiotonic activity in reserpine-pretreated and spontaneously beating rat atria assessed as chronotropic activity by measuring contractile frequency rate at 1 uM (Rvb = 100%)2015Bioorganic & medicinal chemistry, Sep-15, Volume: 23, Issue:18
Design and discovery of 2-(4-(1H-tetrazol-5-yl)-1H-pyrazol-1-yl)-4-(4-phenyl)thiazole derivatives as cardiotonic agents via inhibition of PDE3.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID460703Positive inotropic activity in isolated reserpine-treated Wistar rat whole atrium assessed as contraction at 100 uM (Rvb=100+/-4%)2010Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2
Design, synthesis and biological evaluation of 6-(benzyloxy)-4-methylquinolin-2(1H)-one derivatives as PDE3 inhibitors.
AID90245Ratio of IC50 of inhibition of platelet aggregation to IC50 of inhibition of platelet PDE1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Inhibitors of cyclic AMP phosphodiesterase. 2. Structural variations of N-cyclohexyl-N-methyl-4-[(1,2,3,5-tetrahydro- 2-oxoimidazo[2,1-b]quinazolin-7-yl)-oxy]butyramide (RS-82856).
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID460692Inhibition of human PDE3A by fluorescence microplate reader2010Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2
Design, synthesis and biological evaluation of 6-(benzyloxy)-4-methylquinolin-2(1H)-one derivatives as PDE3 inhibitors.
AID460707Positive inotropic activity in isolated reserpine-treated Wistar rat whole atrium assessed as heart rate at 1 uM (Rvb=100+/-3%)2010Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2
Design, synthesis and biological evaluation of 6-(benzyloxy)-4-methylquinolin-2(1H)-one derivatives as PDE3 inhibitors.
AID240820Inhibitory concentration against IKr potassium channel2004Bioorganic & medicinal chemistry letters, Sep-20, Volume: 14, Issue:18
The pharmacophore hypotheses of I(Kr) potassium channel blockers: novel class III antiarrhythmic agents.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID220009Inhibition of cAMP Phosphodiesterase enzyme.1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
In search of the digitalis replacement.
AID460693Inhibition of human PDE3B by fluorescence microplate reader2010Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2
Design, synthesis and biological evaluation of 6-(benzyloxy)-4-methylquinolin-2(1H)-one derivatives as PDE3 inhibitors.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID460709Positive inotropic activity in isolated reserpine-treated Wistar rat whole atrium assessed as heart rate at 100 uM (Rvb=100+/-3%)2010Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2
Design, synthesis and biological evaluation of 6-(benzyloxy)-4-methylquinolin-2(1H)-one derivatives as PDE3 inhibitors.
AID408340Inhibition of human ERG expressed in CHO cells by whole cell patch clamp technique2008Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11
Support vector machines classification of hERG liabilities based on atom types.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID219850In vivo inhibition of cyclic AMP phosphodiesterase from human platelets1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Inhibitors of cyclic AMP phosphodiesterase. 2. Structural variations of N-cyclohexyl-N-methyl-4-[(1,2,3,5-tetrahydro- 2-oxoimidazo[2,1-b]quinazolin-7-yl)-oxy]butyramide (RS-82856).
AID158567Inhibition of crude canine cardiac c-AMP phosphodiesterase1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Cardiotonic agents. 5. Fragments from the heterocycle-phenyl-imidazole pharmacophore.
AID1245200Inhibition of human PDE3A using FAM-cAMP by fluorescence polarization assay2015Bioorganic & medicinal chemistry, Sep-15, Volume: 23, Issue:18
Design and discovery of 2-(4-(1H-tetrazol-5-yl)-1H-pyrazol-1-yl)-4-(4-phenyl)thiazole derivatives as cardiotonic agents via inhibition of PDE3.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1245203Cardiotonic activity in reserpine-pretreated and spontaneously beating rat atria assessed as inotropic activity by measuring contractile force at 10 uM (Rvb = 100%)2015Bioorganic & medicinal chemistry, Sep-15, Volume: 23, Issue:18
Design and discovery of 2-(4-(1H-tetrazol-5-yl)-1H-pyrazol-1-yl)-4-(4-phenyl)thiazole derivatives as cardiotonic agents via inhibition of PDE3.
AID460701Positive inotropic activity in isolated reserpine-treated Wistar rat whole atrium assessed as contraction at 1 uM (Rvb=100+/-4%)2010Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2
Design, synthesis and biological evaluation of 6-(benzyloxy)-4-methylquinolin-2(1H)-one derivatives as PDE3 inhibitors.
AID1245201Inhibition of human PDE3B using FAM-cAMP by fluorescence polarization assay2015Bioorganic & medicinal chemistry, Sep-15, Volume: 23, Issue:18
Design and discovery of 2-(4-(1H-tetrazol-5-yl)-1H-pyrazol-1-yl)-4-(4-phenyl)thiazole derivatives as cardiotonic agents via inhibition of PDE3.
AID161281Inhibition of human Potassium channel HERG expressed in mammalian cells2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1245206Toxic cardiotonic activity in reserpine-pretreated and spontaneously beating rat atria assessed as chronotropic activity by measuring contractile frequency rate at 10 uM (Rvb = 100%)2015Bioorganic & medicinal chemistry, Sep-15, Volume: 23, Issue:18
Design and discovery of 2-(4-(1H-tetrazol-5-yl)-1H-pyrazol-1-yl)-4-(4-phenyl)thiazole derivatives as cardiotonic agents via inhibition of PDE3.
AID460702Positive inotropic activity in isolated reserpine-treated Wistar rat whole atrium assessed as contraction at 10 uM (Rvb=100+/-4%)2010Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2
Design, synthesis and biological evaluation of 6-(benzyloxy)-4-methylquinolin-2(1H)-one derivatives as PDE3 inhibitors.
AID1245207Toxic cardiotonic activity in reserpine-pretreated and spontaneously beating rat atria assessed as chronotropic activity by measuring contractile frequency rate at 100 uM (Rvb = 100%)2015Bioorganic & medicinal chemistry, Sep-15, Volume: 23, Issue:18
Design and discovery of 2-(4-(1H-tetrazol-5-yl)-1H-pyrazol-1-yl)-4-(4-phenyl)thiazole derivatives as cardiotonic agents via inhibition of PDE3.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1245202Cardiotonic activity in reserpine-pretreated and spontaneously beating rat atria assessed as inotropic activity by measuring contractile force at 1 uM (Rvb = 100%)2015Bioorganic & medicinal chemistry, Sep-15, Volume: 23, Issue:18
Design and discovery of 2-(4-(1H-tetrazol-5-yl)-1H-pyrazol-1-yl)-4-(4-phenyl)thiazole derivatives as cardiotonic agents via inhibition of PDE3.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID40532Inotropic effect by direct or indirect activation of beta-1 adrenergic receptor; ND is no data1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
In search of the digitalis replacement.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (203)

TimeframeStudies, This Drug (%)All Drugs %
pre-199042 (20.69)18.7374
1990's112 (55.17)18.2507
2000's39 (19.21)29.6817
2010's8 (3.94)24.3611
2020's2 (0.99)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.28

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.28 (24.57)
Research Supply Index5.45 (2.92)
Research Growth Index4.54 (4.65)
Search Engine Demand Index34.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (26.28)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials17 (7.91%)5.53%
Reviews27 (12.56%)6.00%
Case Studies3 (1.40%)4.05%
Observational0 (0.00%)0.25%
Other168 (78.14%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Long-Term, Follow-On Safety Study of Four Doses of OPC-8212 (Vesnarinone) in HIV-Infected Persons [NCT00002130]0 participants InterventionalCompleted
A Pilot Study of OPC-8212 (Vesnarinone) in Persons With AIDS-Related Kaposi's Sarcoma [NCT00002131]Phase 228 participants InterventionalCompleted
A Phase I Safety and Tolerability Study of Four Doses of OPC-8212 (Vesnarinone) in Advanced HIV Disease [NCT00002337]Phase 156 participants InterventionalCompleted
A Phase I Study of Three Doses of OPC-8212 (Vesnarinone) in HIV-Infected Persons With CD4+ Cell Number > 300 Cells/mm3 [NCT00002129]Phase 136 participants InterventionalCompleted
[information is prepared from clinicaltrials.gov, extracted Sep-2024]